Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$84.93 USD

84.93
2,354,700

+0.61 (0.72%)

Updated Aug 9, 2024 04:00 PM ET

After-Market: $85.09 +0.16 (0.19%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Stock Market News for May 19, 2020

by Zacks Equity Research

Wall Street rebounded impressively on Monday buoyed by an encouraging early-stage clinical trial data for a potential coronavirus vaccine.

Ritujay Ghosh headshot

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

by Ritujay Ghosh

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

Nalak Das headshot

Major Indexes Defying "Sell in May" Adage: 5 Growth Picks

by Nalak Das

Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."

Madeleine Johnson headshot

Here's Why Moderna (MRNA) Stock is Jumping Today

by Madeleine Johnson

On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.

Benjamin Rains headshot

Buy Nvidia & Alibaba Stock Before Earnings for Coronavirus Resilience?

by Benjamin Rains

We dive into Nvidia and Alibaba ahead of their quarterly earnings results that are due out this week to help investors decide if either stock might worth buying...

Neena Mishra headshot

Moderna Soars: Biotech ETFs in Focus

by Neena Mishra

Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.

Market Gains on Powell's Speech and Moderna's Vaccine

by Zacks Equity Research

Market Gains on Powell's Speech and Moderna's Vaccine.

Mark Vickery headshot

Moderna (MRNA) COVID-19 Vaccine Looks Promising

by Mark Vickery

This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

Jeremy Mullin headshot

Traders Focus on Powell's Comments

by Jeremy Mullin

Futures are flying high before the bell.

David Borun headshot

Stocks Take a Breather, but Good Weekend News Promises a Boost

by David Borun

Positive comments from the Fed Chairman and promising vaccine trial results provide a chance for a meaningful rally.

Neena Mishra headshot

Healthcare Tech & Robotics ETFs in Focus amid COVID-19 Crisis

by Neena Mishra

The pandemic will forever transform our lives; here are some areas that may benefit.

The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills

by Zacks Equity Research

The Zacks Analyst Blog Highlights: NVIDIA, Moderna, Clorox, Campbell Soup and General Mills

Nalak Das headshot

Rebalance Your Portfolio to Counter Dilemma Over Recovery

by Nalak Das

At this stage, a combination of aggressive and defensive stocks after filtering with proper selection criteria will be prudent for one's portfolio.

Novovax (NVAX) Surges on CEPI Funding for Coronavirus Vaccine

by Zacks Equity Research

Novovax (NVAX) is set to receive funding of up to $388 million from CEPI to support clinical development and scaling up of production of its coronavirus vaccine candidate.

Zacks.com headshot

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

by Zacks.com

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Wayfair, Chegg, Moderna, Quidel and Clorox

Sweta Jaiswal, FRM headshot

Novavax Soars on Coronavirus Vaccine Funding: ETFs to Gain

by Sweta Jaiswal, FRM

Novavax received funding for the coronavirus vaccine and also delivered better-than-expected Q1 results resulting in a stock rally in yesterday's trading session.

Sanghamitra Saha headshot

6 Leveraged ETFs Up At Least 25% Last Week

by Sanghamitra Saha

Oil, tech and biotech caused a rally in the leveraged ETF space last week.

Nalak Das headshot

An Outstanding Week for Market Amid Record Job Losses: 5 Picks

by Nalak Das

Market's worst is behind us as negative estimates are already factored in valuations.

Sanghamitra Saha headshot

6 ETF Areas Beating S&P 500 in 2020

by Sanghamitra Saha

The S&P 500 is down 10.8% this year, after a massive recovery in April. But these ETF areas have beaten the S&P 500 this year.

Moderna (MRNA) Q1 Loss Narrows, Revenues Miss Estimates

by Zacks Equity Research

Moderna (MRNA) reports narrower-than-expected first-quarter loss. The company plans to initiate phase II study on coronavirus vaccine soon.

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi

Moderna (MRNA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Moderna (MRNA) delivered earnings and revenue surprises of 5.41% and -53.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Neena Mishra headshot

Biotech ETFs Poised to Benefit From Coronavirus

by Neena Mishra

Rising investor interest in coronavirus related stocks will benefit these ETFs